![Loni da Silva](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Loni da Silva
Consigliere Generale presso OYSR POIN
Profilo
Loni da Silva is currently working as the Senior Vice President-Regulatory Affairs at Oyster Point Pharma, Inc. Previously, she held positions as the Senior Director-Regulatory Affairs at Hoffmann-La Roche, Inc., Vice President-Global Regulatory Affairs at Oldtech, Inc. from 2000 to 2005, Vice President-Regulatory Affairs at Pharmasset, Inc. from 2005 to 2012, and Senior Vice President-Global Regulatory Affairs at IVERIC bio, Inc. In terms of education, Ms. da Silva has a graduate degree from Long Island University and an undergraduate degree from The Pennsylvania State University.
Posizioni attive di Loni da Silva
Società | Posizione | Inizio |
---|---|---|
OYSR POIN | Consigliere Generale | - |
Precedenti posizioni note di Loni da Silva
Società | Posizione | Fine |
---|---|---|
Oldtech, Inc.
![]() Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Consigliere Generale | 01/01/2005 |
Hoffmann-La Roche, Inc.
![]() Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Consigliere Generale | - |
IVERIC BIO, INC. | Consigliere Generale | - |
Pharmasset, Inc.
![]() Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Consigliere Generale | - |
Formazione di Loni da Silva
The Pennsylvania State University | Undergraduate Degree |
Long Island University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 5 |
---|---|
Oldtech, Inc.
![]() Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Health Technology |
Pharmasset, Inc.
![]() Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Health Technology |
IVERIC bio, Inc.
![]() IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
Hoffmann-La Roche, Inc.
![]() Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Oyster Point Pharma, Inc.
![]() Oyster Point Pharma, Inc. Pharmaceuticals: MajorHealth Technology Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ. | Health Technology |
- Borsa valori
- Insiders
- Loni da Silva